Clinical Trial 分子量 406.48 Formula C22H26N6O2 CAS 号 2589531-76-8 运输条件 Room temperature in continental US; may vary elsewhere. 储存方式 Powder-20°C 3 years 4°C 2 years In solvent-80°C 6 months -20°C 1 month 溶解性数据 In Vitro: DMSO : 12.5 mg/mL (30.75 mM; ultras...
Measurement of PARylation inhibition has been used to determine the pharmacodynamics (PD) of PARPi in clinical trials, but the assays used were insensitive and non-specific. Here we report on a new, highly sensitive and specific PARylation assay as evaluated in the PETRA trial (NCT04644068)....
Enrollment began in September 2023; sites across North America, Europe and Australia will enroll up to 120 patients.Clinical trial information: NCT05938270.Simon PaceyCambridge University Hospitals NHS Foundation Trust & University of Cambridge, Cambridge, United KingdomKim N. Chi...
The study is ongoing in Australia, Italy, UK, and USA.Clinical trial information: NCT05367440.Safety Parameters, n (%)mCRPC(n=32)mCSPC(n=16)All pts*(N=48)Any AE31 (96.9)16 (100.0)47 (97.9)Treatment-related AE28 (87.5)14 (87.5)42 (87.5)Any AE Grade ≥39 (28.1)5 (31.3)14 (...
Background: AZD5305 is a potent, highly selective PARP1 inhibitor and trapper with superior preclinical tolerability, target engagement and efficacy vs 1st generation dual PARP1/2 inhibitors (PARPi). This is the first report of the ongoing Phase 1/2a PETRA (NCT04644068) trial.Methods: Pts ...